Ear, Nose and Throat (ENT)
Current Basic Science Research
Current research is being performed by Dr. Ward’s research group in conjunction with a bioengineering group to develop an implantable biomedical device that can restore facial function.
Current Clinical Research
Current research efforts are based on improvement in the treatment of patients with facial paralysis and synkinesis. Read about the studies below:
- Study to determine difference in effects of botulinum myomodulators in the treatment of facial synkinesis
- Study to determine the incidence of depression in patients with facial synkinesis and the response of the depression with botulinum myomodulator therapy
Study to determine difference in effects of botulinum myomodulators in the treatment of facial synkinesis
The purpose of this research study is to compare three commercially available botulinum neuromodulators (botox products) in a randomized study. We are doing this because the three botulinum neuromodulators have not been compared for the treatment of facial synkinesis. All of them are available on the market, approved for use and not experimental.
Treatment given for the condition is not experimental or part of the research. The study researches a completion of two questionnaires that rate facial movement and improvement after treatment. The study participant is asked to complete two questionnaires (the FaCE and Synkinisis Assessment) in the clinic before the injection and again the same questionnaires at week 1, week 2 and week 4 after their injection. These questionnaires are standard use in our clinic and were not developed just for this study. The information collected from the questionnaires will be compared to other questionnaire results.
Participants will not know which botulinum neuromodulator injection they are receiving for the treatment of their facial synkinesis until the end of the study and then they may ask which product was used. Assignments to receive one of the three neuromodulators is random. All work in a similar fashion and will not appreciably affect the risks associated with the treatments.